Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults

Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.43.7.1686
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Microbiology